Doc code IDS

PTO/SB/05e (12-08)
Approved for use through 01/31/2009 OMB 0651-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Doc description: Information Disclosure Statement (IDS) Filed Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10684633	
	Filing Date		2003-10-14	
NFORMATION DISCLOSURE	First Named Inventor Michael S. Kopreski		nel S. Kopreski	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1634	
not for debiliosion and of or it may	Examiner Name	Lu, Fr	rank Wei Min	
	Attorney Docket Numb	er	00-1312-L	

				U.:	S.PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Rind Issue Date Name of Patentee or Applicant Rele			Releva	Columns,Lines where ant Passages or Relev s Appear		
	1								
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information	please click the	Add button.	_	Add	
			U.S.P	ATENT APP	LICATION PUB	LICATIONS		Remove	
Examiner Cite Publication Number Kind Code1 Date Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where ant Passages or Releves Appear						
	1								
If you wisl	h to a	dd additional U.S. Publ	ished Ap				d button		
				FOREIGN P	ATENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т.
	1								
If you wisi	h to a	dd additional Foreign P	atent Do	cument citati	on information p	lease click the Add	button	Add	1
			NO	4-PATENT LI	TERATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symposiun	n, catalog, etc),				Τs

1		Rajagopal et al. (1995), Int. J. Cancer 62: 661-667.	
2	2	Dahiya et al. (1996), Urology 48: 963-970.	
3	3	LeRiche et al. (1996), J. Cim. Endocrinot. Metab. 81: 656-662.	
4	ı	Pfeiffer et al. (1997), Int. J. Cancer 72: 581-586.	
5	5	De Luca et al. (2000), Clin. Cancer Res. 6: 1439-1444.	
6	3	Schlegel et al. (1994), Int. J. Cancer 56: 72-77.	
7	,	Worm et al. (1999), Hum. Pathol. 30: 222-227.	
8	3	Pawlowski et al. (2000), Cancer Detect. Prev. 24: 212-223.	
9	,	Walch et al. (2001), Lab. Invest. 81: 791-801.	
1	10	Sarkar et al. (1983), Diagn. Mol. Pathol. 2: 210-218.	
		Gehharrif et al. (1998). Binchem. Binches. Res. Comm. 247-319-323.	П

	Application Number		10684633		
	Filing Date		2003-10-14	Ī	
INFORMATION DISCLOSURE	First Named Inventor	Micha	ael S. Kopreski		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1634		
(Not for Submission under 37 GFR 1.33)	Examiner Name	Lu, Fr	rank Wei Min		
	Attorney Docket Number		00-1312-L		

	12	Revillion et al. (1997), Clin. Chem. 43: 2114-2120.	
	13	Schneeberger et al. (1996), Anticancer Res. 16: 849-852.	
	14	Kraehn et al. (2001), Br. J. Cancer 84: 72-79.	
	15	Gamberi et al. (1998), Oncology 55: 556-563.	
	16	Sagawa et al. (2001), Cancer Letters 168: 45-50.	
	17	Christoph et al. (1999). Int. J. Cancer 84: 169-173.	
	18	Latil et al. (2000), Int. J. Cancer 89: 172-176.	
	19	Zhou et al. (1996), J. Brol. Chem. 271: 10760-10766.	
	20	Kozu et al. (1995), Genomics 25: 365-371.	
	21	Cocke et al. (2001), Clin. Chem. 47: 369, abstract 51.	
	22	Poon et al. (2001), Clin. Chem. 47: 363, abstract 11.	

Application Number 10684633
Filing Date 2003-10-14
First Named Inventor Methase S. Kopresis
Art Unit 1634
At Unit 1634
Examiner Name | Lu, Frank Wei Min
Attorney Docket Number 00-312-L

	23	Urnovitz et al. (1999), Clin. Diag. Lab. Immunology 6: 330-335.	
	24	Zhao et al. (1994), Circulation 90: 677-685.	
	25	Dhillon et al. (2001), Exp. Neurol. 170: 140-148.	
	26	Fleischhacker et al. (2001), Clm. Chem. 47: 369 (Oral Presentation).	×
	27	El-Hernawy et al. (2004), Clin. Chem. 50(3): 584-573.	
	28	Tschentscher et al. (2000), Int. J. Clin. Lab. Res. 30(1): 13-15.	
	29	Missov et al. (1999), Clinica Chimica Acta 284: 175-185.	
	30	Sarko et al. (2002), J. Emerg. Med. 23(1): 57-65.	
	31	Jurlander et al. (2000), Eur. Hearl J. 21: 382-289.	
	32	Rainer et al. (2003), Clin. Chem. 50(1): 206-208.	
	22	Toward and (1995) I Mr.I Call Confer 177, 2222 2220	

	Application Number		10684633	
	Filing Date		2003-10-14	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Micha	ael S. Kopreski	
	Art Unit		1634	
(Not for Submission under 57 GFR 1.33)	Examiner Name	Lu, Fr	rank Wei Min	
	Attorney Docket Number		00-1312-L	
			T	

34	Mizuno et al. (2001), Blood 97(5): 1172-1179.	
35	Meiki et al. (1996), Leukemia 12: 311-316.	
36	Lee et al. (1996), Proc. Natl. Acad. Sci. U. S. A. 93: 10366-10370.	
37	Eads et al. (1999), Cancer Res. 59: 2302-2306.	
38	Robertson et al. (1999), Nucleic Acids Res. 27(11): 2291-2298.	
39	Fleischhacker and Schmidt (2007), Biochim. Biophys. Acta 1775: 181-232.	
40	Lion et al. (1995), Leukemia 9: 1353-1360.	
41	El-Deiry, et al. (1991), Proc. Natl. Acad. Soi. U. S. A. 88: 3470-3474.	
42	Lo et al. (1999), Clin. Chem. 45(8): 1292-1294.	
43	Chen et al. (1999), Int. J. Cancer 83: 10-14.	
44	Sailo et al. (2001), Hepatology 33: 561-568.	П

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10684633				
iling Date		2003-10-14				
irst Named Inventor Micha		el S. Kopreski				
Art Unit		1634				
Examiner Name Lu, Fr		ank Wei Min				
Attorney Docket Numb	er	00-1312-L				

Date Considered

	45	Alouche et al. (1995), Leukemia 9(1): 77-86.					
	46	Garbarz et al. (1992), Blood 80(4): 1066-1073.					
	47	Gun et al. (1975), Biochemical Medicine 13(3): 224-230.					
	48	Kopreski et al. (1999), Clin. Canoer Res. 5: 1961-1965.					
	49	Kopreski et al. (2000), Ann. N. Y. Acad. Sci. 906: 124-128.					
	50	Lelizei et al. (1998), Clin. Cancer Res. 4: 3037-3043.					
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add					

1 See Kind Codes of USPTO Patient Documents at www.LISPTO.GDV or MPEP 901.04. ² Enter office that issued the document, by the lave-letter code (WIPO Standard ST.3). ³ Fea Japanese point document, be reduced or the year of the ringer of the Engent must preced in lesseral number of the patient Counters!. Figure 1. The patient Counters! or the

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature